Meishuxukeji's KnowDrug.ai Selected for WAIC 2026 Data Empowerment Intelligent Body Practices
On July 19th, the 'Data Elements x Industry Intelligent Bodies' sub-forum of the 2026 World Artificial Intelligence Conference (WAIC 2026) commenced in Shanghai. During the forum, the 2026 Data Elements Empowerment Intelligent Body Typical Practices were announced. Meishuxukeji, a subsidiary of Meixin Health, had its independently developed 'KnowDrug.ai' intelligent body successfully selected. This recognition stems from its professional data advantages in the medical insurance sector and its applications in patient services for innovative drugs. KnowDrug.ai has established an intelligent service system that spans crucial stages including disease awareness, patient management, and medication support. The platform aims to bridge the gap between pharmaceutical companies, healthcare services, and patients. By doing so, it seeks to simultaneously enhance the commercial value of innovative drugs and improve patient health outcomes.
The selection of KnowDrug.ai for WAIC 2026 highlights the growing trend of leveraging specialized data within vertical industries to create intelligent solutions. This initiative underscores the potential of data elements to drive innovation in AI applications, particularly in complex sectors like healthcare and pharmaceuticals. The platform's focus on connecting pharmaceutical enterprises, healthcare providers, and patients suggests a strategic approach to optimizing the drug development and patient support lifecycle. As AI continues to mature, such data-driven intelligent bodies are likely to become pivotal in addressing systemic inefficiencies and improving service delivery across various industries, fostering a more integrated and patient-centric healthcare ecosystem.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.